tiprankstipranks
Trending News
More News >
Opthea Limited Sponsored ADR (OPT)
NASDAQ:OPT
Advertisement

Opthea Limited Sponsored ADR (OPT) Price & Analysis

Compare
196 Followers

OPT Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Bears Say
Analyst DowngradeThe stock was downgraded from a price target of $12 to $1 following the negative trial results.
Clinical TrialsThe Phase 3 COAST trial of sozinibercept failed to meet its primary endpoint, which is disappointing for its development in wet age-related macular degeneration.
Financial ObligationsOpthea could be required to pay four times the amounts received under the Development Funding Agreement, which would severely impact the company's solvency.

Opthea Limited Sponsored ADR News

OPT FAQ

What was Opthea Limited Sponsored ADR’s price range in the past 12 months?
Opthea Limited Sponsored ADR lowest stock price was $2.84 and its highest was $6.30 in the past 12 months.
    What is Opthea Limited Sponsored ADR’s market cap?
    Opthea Limited Sponsored ADR’s market cap is $481.10M.
      When is Opthea Limited Sponsored ADR’s upcoming earnings report date?
      Opthea Limited Sponsored ADR’s upcoming earnings report date is Feb 26, 2026 which is in 181 days.
        How were Opthea Limited Sponsored ADR’s earnings last quarter?
        Currently, no data Available
        Is Opthea Limited Sponsored ADR overvalued?
        According to Wall Street analysts Opthea Limited Sponsored ADR’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Opthea Limited Sponsored ADR pay dividends?
          Opthea Limited Sponsored ADR does not currently pay dividends.
          What is Opthea Limited Sponsored ADR’s EPS estimate?
          Opthea Limited Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Opthea Limited Sponsored ADR have?
          Opthea Limited Sponsored ADR has 153,910,920 shares outstanding.
            What happened to Opthea Limited Sponsored ADR’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Opthea Limited Sponsored ADR?
            Currently, no hedge funds are holding shares in OPT

            Company Description

            Opthea Limited Sponsored ADR

            Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

            Opthea Limited Sponsored ADR (OPT) Earnings & Revenues

            Similar Stocks
            Company
            Price & Change
            Follow
            Cormedix
            Sinovac Biotech
            Urogen Pharma
            Arvinas Holding Company
            Cullinan Management

            Ownership Overview

            <0.01%4.74%95.26%
            Insiders
            4.74% Other Institutional Investors
            95.26% Public Companies and
            Individual Investors

            Options Prices

            Currently, No data available
            ---
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis